Aurobindo Pharma
Financials
Estimates*
INR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|
Revenues | 245.6b | 233.7b | 246.2b | 287.0b | 316.4b | 348.1b | 364.1b |
% growth | 8 % | (5 %) | 5 % | 17 % | 10 % | 10 % | 5 % |
EBITDA | 53.8b | 46.2b | 40.0b | 63.8b | 68.9b | 78.0b | 78.9b |
% EBITDA margin | 22 % | 20 % | 16 % | 22 % | 22 % | 22 % | 22 % |
Profit | 53.3b | 26.5b | 19.3b | 31.7b | 39.3b | 46.6b | 47.6b |
% profit margin | 22 % | 11 % | 8 % | 11 % | 12 % | 13 % | 13 % |
EV / revenue | 2.1x | 1.6x | 1.2x | 2.2x | 2.8x | 2.5x | 2.3x |
EV / EBITDA | 9.6x | 8.1x | 7.3x | 10.0x | 12.9x | 11.0x | 10.4x |
R&D budget | 688m | 652m | 395m | 756m | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
Total Funding | - |
Related Content
Recent News about Aurobindo Pharma
EditAurobindo Pharma is a leading global pharmaceutical company specializing in the production of generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in the highly competitive pharmaceutical market, serving a diverse range of clients including healthcare providers, pharmacies, and distributors worldwide. Aurobindo's business model focuses on leveraging a globally competitive cost base and a talented team of scientists to develop and commercialize affordable pharmaceutical products. The company has a strong presence in research and development, with seven R&D centers that drive innovation across multiple therapeutic areas and delivery technologies. Aurobindo generates revenue through the sale of its generic formulations and APIs, which are manufactured in facilities approved by the US FDA and other global regulatory bodies. The company's growth is supported by its ability to launch cost-effective drugs and maintain a robust product portfolio that meets the needs of the global healthcare market.
Keywords: generic pharmaceuticals, Active Pharmaceutical Ingredients, cost-effective, drug development, global market, healthcare providers, R&D centers, therapeutic areas, FDA approved, affordable products.